Nifuratel: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
m (Protected "Nifuratel": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{Drugbox
{{Drugbox
| IUPAC_name       = 5-[(methylthio)methyl]-3-{[(1''E'')-(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
| Watchedfields = changed
| image             = Nifuratel.png
| verifiedrevid = 444454940
| CAS_number        = 4936-47-4
| IUPAC_name = 5-[(Methylthio)methyl]-3-{[(1''E'')-(5-nitro-2-furyl)methylene]amino}-1,3-oxazolidin-2-one
| ATC_prefix        = G01
| image = Nifurate.png
| ATC_suffix        = AX05
| width = 250
| PubChem          = 6433427
 
| DrugBank          =
<!--Clinical data-->
| C=10|H=11|N=3|O=5|S=1
| tradename =
| molecular_weight  = 285.28 g/mol
| Drugs.com = {{drugs.com|international|nifuratel}}
| bioavailability  =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| protein_bound    =
| pregnancy_US = <!-- A / B            / C / D / X -->
| metabolism        =
| pregnancy_category =   
| elimination_half-life =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| excretion        =
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| pregnancy_AU     = <!-- A / B1 / B2 / B3 / C / D / X -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| pregnancy_US     = <!-- A / B            / C / D / X -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| pregnancy_category=   
| legal_status = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| routes_of_administration = 
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
 
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
<!--Pharmacokinetic data-->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| bioavailability = 
| legal_status      =  
| protein_bound = 
| routes_of_administration =  
| metabolism = 
| elimination_half-life = 
| excretion = 
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 4936-47-4
| ATC_prefix = G01
| ATC_suffix = AX05
| PubChem = 6433427
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U60U6P08SP
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01050
| ChemSpiderID     = 4938579
 
<!--Chemical data-->
| C=10 | H=11 | N=3 | O=5 | S=1
| molecular_weight = 285.28 g/mol
| smiles            = CSCC1CN(C(=O)O1)/N=C/C2=CC=C(O2)[N+](=O)[O-]
| InChI            = 1/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+
| InChIKey          = SRQKTCXJCCHINN-NYYWCZLTBV
| StdInChI          = 1S/C10H11N3O5S/c1-19-6-8-5-12(10(14)18-8)11-4-7-2-3-9(17-7)13(15)16/h2-4,8H,5-6H2,1H3/b11-4+
| StdInChIKey      = SRQKTCXJCCHINN-NYYWCZLTSA-N
 
}}
}}
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}
==Overview==
'''Nifuratel''' (brand name '''Macmiror''', or—in combination with [[nystatin]]—'''Macmiror Complex''') is a drug used in [[gynecology]]. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States.


Nifuratel appears to have a broad antibacterial spectrum of action and is effective against ''Chlamydia trachomatis'' and ''Mycoplasma spp.'' as well as fungal infections from ''Candida spp.''<ref> Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey </ref>


'''Nifuratel''' is a drug used in [[gynecology]].
Taken orally, or as a vaginal pessary, it is used in the treatment of a wide range of infections of the genito-urinary tract, especially if there is no accurate diagnosis available. For example it may be used in the treatment of women exhibiting vaginal discharge where there is uncertainty as to whether the cause is ''Trichomonas vaginalis'' or ''Candida'' strains such as ''Candida albicans''.  


Side effects appear to be minimal or non-existent and it has a safe toxicological profile.<ref> Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review.  Werner Mendling,  Federico Mailland
Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany. </ref>


==References==
{{Reflist|2}}


{{Gynecological anti-infectives and antiseptics}}
{{Gynecological anti-infectives and antiseptics}}


[[Category:Furans]]
[[Category:Thioethers]]
[[Category:Nitro compounds]]
[[Category:Drug]]
 
{{WH}}
{{WS}}

Latest revision as of 16:48, 20 August 2015

Nifuratel
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H11N3O5S
Molar mass285.28 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Nifuratel

Articles

Most recent articles on Nifuratel

Most cited articles on Nifuratel

Review articles on Nifuratel

Articles on Nifuratel in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Nifuratel

Images of Nifuratel

Photos of Nifuratel

Podcasts & MP3s on Nifuratel

Videos on Nifuratel

Evidence Based Medicine

Cochrane Collaboration on Nifuratel

Bandolier on Nifuratel

TRIP on Nifuratel

Clinical Trials

Ongoing Trials on Nifuratel at Clinical Trials.gov

Trial results on Nifuratel

Clinical Trials on Nifuratel at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Nifuratel

NICE Guidance on Nifuratel

NHS PRODIGY Guidance

FDA on Nifuratel

CDC on Nifuratel

Books

Books on Nifuratel

News

Nifuratel in the news

Be alerted to news on Nifuratel

News trends on Nifuratel

Commentary

Blogs on Nifuratel

Definitions

Definitions of Nifuratel

Patient Resources / Community

Patient resources on Nifuratel

Discussion groups on Nifuratel

Patient Handouts on Nifuratel

Directions to Hospitals Treating Nifuratel

Risk calculators and risk factors for Nifuratel

Healthcare Provider Resources

Symptoms of Nifuratel

Causes & Risk Factors for Nifuratel

Diagnostic studies for Nifuratel

Treatment of Nifuratel

Continuing Medical Education (CME)

CME Programs on Nifuratel

International

Nifuratel en Espanol

Nifuratel en Francais

Business

Nifuratel in the Marketplace

Patents on Nifuratel

Experimental / Informatics

List of terms related to Nifuratel

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nifuratel (brand name Macmiror, or—in combination with nystatin—Macmiror Complex) is a drug used in gynecology. It is a local antiprotozoal and antifungal agent that may also be given orally. Nifuratel is not approved for use in the United States.

Nifuratel appears to have a broad antibacterial spectrum of action and is effective against Chlamydia trachomatis and Mycoplasma spp. as well as fungal infections from Candida spp.[1]

Taken orally, or as a vaginal pessary, it is used in the treatment of a wide range of infections of the genito-urinary tract, especially if there is no accurate diagnosis available. For example it may be used in the treatment of women exhibiting vaginal discharge where there is uncertainty as to whether the cause is Trichomonas vaginalis or Candida strains such as Candida albicans.

Side effects appear to be minimal or non-existent and it has a safe toxicological profile.[2]

References

  1. ↑ Treatment of candidal urinary tract infection with nifuratel. R N Grüneberg, A Leakey
  2. ↑ Microbiological and pharmaco-toxicological profile of nifuratel and its favourable risk/benefit ratio for the treatment of vulvo-vaginal infections. A review. Werner Mendling, Federico Mailland Klinik für Frauenheilkunde und Geburtshilfe, Klinikum Am Urban, Berlin, Germany.
Retrieved from "https://www.wikidoc.org/index.php?title=Nifuratel&oldid=1137130"